A High Proportion of Exacerbation-Prone Patients With Uncontrolled Eosinophilic Asthma Receiving IV Reslizumab Experienced Zero Asthma Exacerbations Through 52 Weeks (Wks) of Treatment

Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2018.12.298
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Clinically Meaningful Improvements in Asthma Control Questionnaire (ACQ) Scores Occur Early, While Asthma-Related Quality of Life (AQLQ) Scores Continue to Improve Over 52 Weeks, Among Patients With Eosinophilic Asthma Receiving IV Reslizumab

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Real-World Safety of Treatment With Mepolizumab and Reslizumab in Patients With Severe Eosinophilic Asthma

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Pharmacoeconomic Analysis of Therapy With Reslizumab in Severe Eosinophilic Asthma

Pulmonologiya
PulmonaryRespiratory Medicine
2018English

Reslizumab: Add-On Therapy for Severe Eosinophilic Asthma

Prescriber
Pharmacology
2017English

Evaluation of Eosinophilic Asthma Patients Without Blood Eosinophil (EOS) Response to Intravenous (IV) Reslizumab in a Post-Hoc Analysis of 52-Week Placebo-Controlled Phase 3 Studies

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Variability in Absolute Blood Eosinophil (EOS) Counts Over 52 Weeks in Patients With Inadequately Controlled Eosinophilic Asthma Receiving Placebo in Two Duplicate Clinical Trials

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Benralizumab Efficacy for Patients With Fixed Airflow Obstruction and Severe, Uncontrolled Eosinophilic Asthma

Annals of Allergy, Asthma and Immunology
Respiratory MedicinePulmonaryAllergyImmunology
2020English

Efficacy and Safety of Treatment With Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma

Allergy: European Journal of Allergy and Clinical Immunology
AllergyImmunology
2020English

Therapeutic Switch From Omalizumab to Mepolizumab in Patients With Uncontrolled Severe Eosinophilic Asthma: Treatment Effect by Prior Omalizumab Treatment Duration

Journal of Allergy and Clinical Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy